David L. Anstaett

Shannon Bloodworth

Brandon M. White

Autumn N. Nero

Gregory D. Miller

Crystal R. Canterbury

Stephanie J. Nelson

Maria A. Stubbings

Andrew S. Chalson

F. Dominic Cerrito

Evangeline Shih

William C. Baton

Charles M. Lizza

Sarah Ann Sullivan

Gabriel P. Brier

Eric C. Stops

Steven J. Corr

Matthew J. Hertko

David L. Moses

Marta Godecki

Brian J. Forsatz

Frank C. Calvosa

Cary Miller

ANDA filing sparks Celgene suit to block generic REVLIMID®. Dr. Reddy’s is accused over drug safety patents requiring a `prescription approval code` system.

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Name	Ratings
Quinn Emanuel Urquhart & Sullivan LLP	L5 A
F. Dominic Cerrito	L5 A
Evangeline Shih	L4 B
Eric C. Stops	L4 C
Andrew S. Chalson	L3 A
Frank C. Calvosa	L3 B
Brian J. Forsatz	L3 C
Gabriel P. Brier	L3 D
Marta Godecki	L1 B
Jones Day	L5 A
Steven J. Corr	L3 A
Matthew J. Hertko	L3 C
Cary Miller	L1 B
Saul Ewing LLP	L3 B
William C. Baton	L5 A
Charles M. Lizza	L5 A
Sarah Ann Sullivan	L5 A
David L. Moses	L4 A

Name	Ratings
DR Reddy's Laboratories Ltd	L1 D
DR Reddys Laboratories Inc	-- -- --

Name	Ratings
Perkins Coie LLP	L5 A
Shannon Bloodworth	L4 B
David L. Anstaett	L4 E
Autumn N. Nero	L4 E
Brandon M. White	L3 B
Maria A. Stubbings	L1 B
Crystal R. Canterbury	L1 C
Stephanie J. Nelson	L1 C
Rivkin Radler LLPLocal	L2 B
Gregory D. Miller	L5 B

2:18-cv-06378

Celgene Corp v. DR Reddy's Laboratories Ltd